key takeaways from keynote-365 in metastatic castration-resistant prostate cancer
Published 5 years ago • 300 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
0:36
treating patients with progressive metastatic castration-resistant prostate cancer
-
5:04
a case of metastatic castration-resistant prostate cancer
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
3:13
treatment options in metastatic prostate cancer
-
11:44
key takeaways | 2022 west oncology conference
-
4:15
keynote-365: pembrolizumab combination therapy for mcrpc
-
2:58
evan yu, md, elaborates on the results from keynote 365 in mcrpc
-
3:24
progression of metastatic prostate cancer defined
-
2:05
dr. yu on initial findings from the keynote-365 trial in mcrpc
-
1:56
dr. oh on targeted treatment in metastatic castration-resistant prostate cancer
-
22:16
understanding non metastatic castration resistant prostate cancer with dr. hamilton
-
1:53
william oh, md, tells us about the results of keynote-365 in mcrpc
-
2:38
keynote-365 cohort a: pembrolizumab plus olaparib in docetaxel-pretreated patients with mcrpc
-
2:40
dr. posadas discusses darolutamide in castration-resistant prostate cancer
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
0:45
sumit k. subudhi, md, phd, considers the outcomes of the keynote 365 study